Literature DB >> 12477420

Cost-benefit evaluation of influenza vaccination in the elderly in the Italian region of Liguria.

R Gasparini1, C Lucioni, P Lai, P Maggioni, L Sticchi, P Durando, P Morelli, I Comino, S Calderisi, P Crovari.   

Abstract

Influenza causes considerable morbidity and mortality and the damage to public health can be considerable. The most effective measures available for the prevention of influenza is vaccination. In most industrialised countries the objective of vaccination is to limit the disease among individuals at risk, especially the elderly. During the winter of 2000/2001, General Practitioners (GPs) monitored 14,818 elderly individuals. The objective was to evaluate the weekly incidence of the disease. Furthermore, we carried out a prospective study on 512 elderly individuals, arranged according to vaccination (304 vaccinated and 208 non-vaccinated), with the main objective of assessing the costs of the disease and the efficacy of vaccination. Finally, in order to assess the percentage of vaccinated elderly individuals, we carried out a telephone survey on 500 subjects. Our clinical surveillance study enabled us to establish that morbidity was particularly low in elderly individuals.The results of the prospective study allowed us to estimate the cost-benefit ratio at 8.22, with a net saving of 110.20 Euros for each vaccinated subject. We were also able to establish that the vaccine coverage among elderly individuals was 63%. Our study, though carried out during a low epidemic year, confirms the economic advantage of vaccination in the elderly.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12477420     DOI: 10.1016/s0264-410x(02)00507-8

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  10 in total

1.  Costs associated with influenza-related hospitalization in the elderly.

Authors:  Núria Torner; Encarna Navas; Núria Soldevila; Diana Toledo; Gemma Navarro; Aurea Morillo; Maria José Pérez; Angela Domínguez
Journal:  Hum Vaccin Immunother       Date:  2016-12-07       Impact factor: 3.452

2.  Safety and immunogenicity of two influenza virus subunit vaccines, with or without MF59 adjuvant, administered to human immunodeficiency virus type 1-seropositive and -seronegative adults.

Authors:  P Durando; D Fenoglio; A Boschini; F Ansaldi; G Icardi; L Sticchi; A Renzoni; P Fabbri; A Ferrera; A Parodi; B Bruzzone; G Gabutti; A Podda; G Del Giudice; E Fragapane; F Indiveri; P Crovari; R Gasparini
Journal:  Clin Vaccine Immunol       Date:  2007-11-14

Review 3.  Inclusion of Safety-Related Issues in Economic Evaluations for Seasonal Influenza Vaccines: A Systematic Review.

Authors:  Tanja Fens; Pieter T de Boer; Eugène P van Puijenbroek; Maarten J Postma
Journal:  Vaccines (Basel)       Date:  2021-02-02

Review 4.  Vaccines for preventing influenza in the elderly.

Authors:  Vittorio Demicheli; Tom Jefferson; Carlo Di Pietrantonj; Eliana Ferroni; Sarah Thorning; Roger E Thomas; Alessandro Rivetti
Journal:  Cochrane Database Syst Rev       Date:  2018-02-01

5.  Cost-benefit analysis of influenza vaccination in a public healthcare unit.

Authors:  Giorgio L Colombo; Antonio Ferro; Marta Vinci; Maria Zordan; Giulio Serra
Journal:  Ther Clin Risk Manag       Date:  2006-06       Impact factor: 2.423

Review 6.  The sustainability of influenza vaccination programs: considerations and perspectives from Italy.

Authors:  A Poscia; J Stojanovic; W Ricciardi
Journal:  J Prev Med Hyg       Date:  2016

7.  Influenza vaccine effectiveness in preventing hospitalisation of individuals 60 years of age and over with laboratory-confirmed influenza, Valencia Region, Spain, influenza season 2016/17.

Authors:  Ainara Mira-Iglesias; F Xavier López-Labrador; Beatriz Guglieri-López; Miguel Tortajada-Girbés; Víctor Baselga-Moreno; Laura Cano; Juan Mollar-Maseres; Mario Carballido-Fernández; Germán Schwarz-Chavarri; Javier Díez-Domingo; Joan Puig-Barberà
Journal:  Euro Surveill       Date:  2018-02

8.  Cost-benefit analysis of vaccination: a comparative analysis of eight approaches for valuing changes to mortality and morbidity risks.

Authors:  Minah Park; Mark Jit; Joseph T Wu
Journal:  BMC Med       Date:  2018-09-05       Impact factor: 8.775

9.  Immunogenicity of H5N1 influenza vaccines in elderly adults: a systematic review and meta-analysis.

Authors:  Ke Zhang; Xiaoxue Wu; Yu Shi; Xiaoqin Gou; Junqiong Huang
Journal:  Hum Vaccin Immunother       Date:  2020-07-21       Impact factor: 3.452

10.  The effect of influenza and pneumococcal vaccination in the elderly on health service utilisation and costs: a claims data-based cohort study.

Authors:  Josephine Storch; Carolin Fleischmann-Struzek; Norman Rose; Thomas Lehmann; Anna Mikolajetz; Srikanth Maddela; Mathias W Pletz; Christina Forstner; Ole Wichmann; Julia Neufeind; Monique Vogel; Konrad Reinhart; Horst Christian Vollmar; Antje Freytag
Journal:  Eur J Health Econ       Date:  2021-07-20
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.